F-star is leading the development of the next generation of therapeutic antibodies and antibody fragments based on its unique Modular Antibody Technology.
Modular Antibody Technology allows the introduction of additional binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Using Modular Antibody Technology, small sized antibody fragments with full antibody functionality and long half life (Fcab™) or full length antibodies with dual functionality (mAb² ™) can be created.
F-star is developing a novel pipeline of products in therapeutic areas such as oncology, inflammation and autoimmune diseases, angiogenesis and other disease areas. F-star is also forming strategic partnerships to further develop the technology.